116 related articles for article (PubMed ID: 11997665)
1. The novel synthetic inhibitor of matrix metalloproteinases Ro 28-2653 induces apoptosis in Dunning tumor cells.
Mangoldt D; Sinn B; Lein M; Krell HW; Schnorr D; Loening SA; Jung K
Apoptosis; 2002 Jun; 7(3):217-20. PubMed ID: 11997665
[TBL] [Abstract][Full Text] [Related]
2. The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model.
Lein M; Jung K; Ortel B; Stephan C; Rothaug W; Juchem R; Johannsen M; Deger S; Schnorr D; Loening S; Krell HW
Oncogene; 2002 Mar; 21(13):2089-96. PubMed ID: 11960381
[TBL] [Abstract][Full Text] [Related]
3. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor.
Maquoi E; Sounni NE; Devy L; Olivier F; Frankenne F; Krell HW; Grams F; Foidart JM; Noël A
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4038-47. PubMed ID: 15217936
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine: tumor-reducing effects on hormone-sensitive prostate cancer in rats.
Abramjuk C; Jung K; Krell HW; Juchem R; Peters R; Taymoorian K; Staack A; Stephan C; Schnorr J; Loening SA; Lein M
Anticancer Drugs; 2005 Sep; 16(8):855-61. PubMed ID: 16096433
[TBL] [Abstract][Full Text] [Related]
5. Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats.
Jung K; Krell HW; Ortel B; Hasan T; Römer A; Schnorr D; Loening SA; Lein M
Prostate; 2003 Feb; 54(3):206-11. PubMed ID: 12518325
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model.
Lokeshwar BL; Selzer MG; Zhu BQ; Block NL; Golub LM
Int J Cancer; 2002 Mar; 98(2):297-309. PubMed ID: 11857423
[TBL] [Abstract][Full Text] [Related]
7. Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model.
Abramjuk C; Lein M; Rothaug W; Krell HW; Loening SA; Jung K
Cancer Chemother Pharmacol; 2007 Feb; 59(2):275-82. PubMed ID: 16758188
[TBL] [Abstract][Full Text] [Related]
8. The matrix metalloproteinases inhibitor Ro 28-2653 [correction of Ro 26-2853] extends survival in transgenic ALS mice.
Lorenzl S; Narr S; Angele B; Krell HW; Gregorio J; Kiaei M; Pfister HW; Beal MF
Exp Neurol; 2006 Jul; 200(1):166-71. PubMed ID: 16516196
[TBL] [Abstract][Full Text] [Related]
9. Effect of the new matrix metalloproteinase inhibitor RO-28-2653 on mitochondrial function.
Opalka JR; Gellerich FN; Kling L; Müller-Beckmann B; Zierz S
Biochem Pharmacol; 2002 Feb; 63(4):725-32. PubMed ID: 11992641
[TBL] [Abstract][Full Text] [Related]
10. Celecoxib inhibits cell growth and modulates the expression of matrix metalloproteinases in human osteosarcoma MG-63 cell line.
Zhou X; Shi X; Ren K; Fan GT; Wu SJ; Zhao JN
Eur Rev Med Pharmacol Sci; 2015 Nov; 19(21):4087-97. PubMed ID: 26592832
[TBL] [Abstract][Full Text] [Related]
11. Reduction of alachlor-induced olfactory mucosal neoplasms by the matrix metalloproteinase inhibitor Ro 28-2653.
Genter MB; Warner BM; Krell HW; Bolon B
Toxicol Pathol; 2005; 33(5):593-9. PubMed ID: 16178123
[TBL] [Abstract][Full Text] [Related]
12. Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model.
Lein M; Jung K; Le DK; Hasan T; Ortel B; Borchert D; Winkelmann B; Schnorr D; Loenings SA
Prostate; 2000 May; 43(2):77-82. PubMed ID: 10754522
[TBL] [Abstract][Full Text] [Related]
13. Prevention of progressive joint destruction in adjuvant induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR217840.
Ishikawa T; Nishigaki F; Miyata S; Hirayama Y; Minoura K; Imanishi J; Neya M; Mizutani T; Imamura Y; Ohkubo Y; Mutoh S
Eur J Pharmacol; 2005 Jan; 508(1-3):239-47. PubMed ID: 15680277
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase inhibitor RO 28-2653 decreases liver metastasis by reduction of MMP-2 and MMP-9 concentration in BOP-induced ductal pancreatic cancer in Syrian Hamsters: inhibition of matrix metalloproteinases in pancreatic cancer.
Kilian M; Gregor JI; Heukamp I; Hanel M; Ahlgrimm M; Schimke I; Kristiansen G; Ommer A; Walz MK; Jacobi CA; Wenger FA
Prostaglandins Leukot Essent Fatty Acids; 2006 Dec; 75(6):429-34. PubMed ID: 17034997
[TBL] [Abstract][Full Text] [Related]
15. SI-27, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity: detection with a variable-pressure scanning electron microscope.
Yoshida D; Noha M; Watanabe K; Sugisaki Y; Teramoto A
Neurosurgery; 2002 Mar; 50(3):578-86; discussion 586-8. PubMed ID: 11841727
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase activity modulates tumor size, cell motility, and cell invasiveness in murine aggressive fibromatosis.
Kong Y; Poon R; Nadesan P; Di Muccio T; Fodde R; Khokha R; Alman BA
Cancer Res; 2004 Aug; 64(16):5795-803. PubMed ID: 15313922
[TBL] [Abstract][Full Text] [Related]
17. High levels of matrix metalloproteinases regulate proliferation and hormone secretion in pituitary cells.
Páez Pereda M; Ledda MF; Goldberg V; Chervín A; Carrizo G; Molina H; Müller A; Renner U; Podhajcer O; Arzt E; Stalla GK
J Clin Endocrinol Metab; 2000 Jan; 85(1):263-9. PubMed ID: 10634397
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis.
Nemeth JA; Yousif R; Herzog M; Che M; Upadhyay J; Shekarriz B; Bhagat S; Mullins C; Fridman R; Cher ML
J Natl Cancer Inst; 2002 Jan; 94(1):17-25. PubMed ID: 11773278
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase inhibitors reduce collagen gel contraction and alpha-smooth muscle actin expression by periodontal ligament cells.
Bildt MM; Bloemen M; Kuijpers-Jagtman AM; Von den Hoff JW
J Periodontal Res; 2009 Apr; 44(2):266-74. PubMed ID: 18973523
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of enzyme activity of and cell-mediated substrate cleavage by membrane type 1 matrix metalloproteinase by newly developed mercaptosulphide inhibitors.
Hurst DR; Schwartz MA; Jin Y; Ghaffari MA; Kozarekar P; Cao J; Sang QX
Biochem J; 2005 Dec; 392(Pt 3):527-36. PubMed ID: 16026329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
